Mice were given phenobarbital (PhB) during neonatal development (NeoB group) and during pre- and neonatal development (Pre- and NeoB group). Prenatal exposure was accomplished transplacentally by feeding the pregnant mothers 3 g PhB/kg milled food on gestation days 9–18. Neonatal exposure was conducted directly by injecting the neonates daily with 50 mg PhB/kg on postnatal days 2–21. The brains of these animals were studied at age 50 days using H & E staining. Consistant with previous studies, NeoB animals had a 14–20% smaller cerebellar layer area than controls, 32% fewer cerebellar Purkinje cells and 34% fewer granule cells than controls. NeoB mice had a 14–18% smaller hippocampal layer and 17% fewer hippocampal pyramidal cells than controls. The number of the hippocampal granule cells was not reduced by early PhB administration. NeoB mice had an 18% smaller cerebral cortex area and 22% fewer cortical cells than controls. The pre- and NeoB animals did not differ from controls in the area of their cerebellar layers, but they did have fewer cerebellar Purkinje and granule cells. Similarly, the Pre- and NeoB animals did not differ from controls in the area of their hippocampal layers, but they had fewer pyramidal cells. The Pre- and NeoB animals had a smaller cerebral layer area than controls but did not differ significantly from controls in the number of cortical neurons. It was suggested that exposure to PhB during prenatal and neonatal periods is not additive. On the contrary, tolerance or compensatory mechanisms may develop after prenatal exposure and lessened the effect of subsequent neonatal PhB exposure.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.